Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Related Articles by Review for PubMed (Select 22751498)

1.

A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.

Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernández H, Burlingame AL, McCormick F.

Genes Dev. 2012 Jul 1;26(13):1421-6. doi: 10.1101/gad.190876.112.

2.

Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.

Brems H, Legius E.

Keio J Med. 2013;62(4):107-12. Epub 2013 Dec 10. Review.

3.

Review and update of SPRED1 mutations causing Legius syndrome.

Brems H, Pasmant E, Van Minkelen R, Wimmer K, Upadhyaya M, Legius E, Messiaen L.

Hum Mutat. 2012 Nov;33(11):1538-46. doi: 10.1002/humu.22152. Epub 2012 Aug 1. Review.

PMID:
22753041
4.

Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.

Abramowicz A, Gos M.

Dev Period Med. 2014 Jul-Sep;18(3):297-306. Review.

5.

[Characterization of the neurofibromatosis type 1 gene and neurofibromin's role in cells].

Sakai A.

Nihon Rinsho. 2000 Jul;58(7):1426-9. Review. Japanese.

PMID:
10921317
6.

Neurofibromatosis 1: closing the GAP between mice and men.

Dasgupta B, Gutmann DH.

Curr Opin Genet Dev. 2003 Feb;13(1):20-7. Review.

PMID:
12573431
7.

Neurofibromatosis type 1: piecing the puzzle together.

Feldkamp MM, Gutmann DH, Guha A.

Can J Neurol Sci. 1998 Aug;25(3):181-91. Review.

PMID:
9706718
8.

Alternative splicing of the neurofibromatosis type I pre-mRNA.

Barron VA, Lou H.

Biosci Rep. 2012 Apr 1;32(2):131-8. doi: 10.1042/BSR20110060. Review.

9.

Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.

Dilworth JT, Kraniak JM, Wojtkowiak JW, Gibbs RA, Borch RF, Tainsky MA, Reiners JJ Jr, Mattingly RR.

Biochem Pharmacol. 2006 Nov 30;72(11):1485-92. Epub 2006 Apr 28. Review.

PMID:
16797490
10.

[Relationship between Spred1 and acute myeloid leukemia].

Zhang Y, Li Y, Zhang R.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Aug;21(4):1083-7. doi: 10.7534/j.issn.1009-2137.2013.04.052. Review. Chinese.

PMID:
23998617
11.

Pigment cell-related manifestations in neurofibromatosis type 1: an overview.

De Schepper S, Boucneau J, Lambert J, Messiaen L, Naeyaert JM.

Pigment Cell Res. 2005 Feb;18(1):13-24. Review.

PMID:
15649148
12.

Recent developments in neurofibromatosis type 1.

Lee MJ, Stephenson DA.

Curr Opin Neurol. 2007 Apr;20(2):135-41. Review.

PMID:
17351482
13.

Neurofibromatosis type 1.

Boyd KP, Korf BR, Theos A.

J Am Acad Dermatol. 2009 Jul;61(1):1-14; quiz 15-6. doi: 10.1016/j.jaad.2008.12.051. Review.

14.

Diagnosis and management of neurofibromatosis type 1.

Korf BR.

Curr Neurol Neurosci Rep. 2001 Mar;1(2):162-7. Review.

PMID:
11898512
16.

Neurofibromatosis type 1: pathology, clinical features and molecular genetics.

von Deimling A, Krone W, Menon AG.

Brain Pathol. 1995 Apr;5(2):153-62. Review.

PMID:
7670656
17.

Type I neurofibromatosis: a geno-oculo-dermatologic update.

Schnur RE.

Curr Opin Ophthalmol. 2012 Sep;23(5):364-72. doi: 10.1097/ICU.0b013e3283570127. Review.

PMID:
22871881
18.

The RASopathies.

Rauen KA.

Annu Rev Genomics Hum Genet. 2013;14:355-69. doi: 10.1146/annurev-genom-091212-153523. Epub 2013 Jul 15. Review.

19.

Legius Syndrome.

Stevenson D, Viskochil D, Mao R.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015.
2010 Oct 14 [updated 2015 Jan 15].

20.

[Rasopathies: developmental disorders that predispose to cancer and skin manifestations].

Hernández-Martín A, Torrelo A.

Actas Dermosifiliogr. 2011 Jul-Aug;102(6):402-16. doi: 10.1016/j.ad.2011.02.010. Epub 2011 May 4. Review. Spanish.

PMID:
21536246
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk